Eisai to Present Latest Data at 10th Clinical Trials on Alzheimer's Diesase

Oct 31, 2017 11:27 JST

Source: Eisai

TOKYO, Oct 31, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest data on its oral dual orexin receptor antagonist lemborexant and its oral beta secretase cleaving enzyme (BACE) inhibitor elenbecestat(1) will be presented at the 10th Clinical Trials on Alzheimer's Disease (CTAD), taking place in Boston, the United States, from November 1 to 4.

At the CTAD meeting, there will be a poster presentation on the characteristics of sleep and wakefulness measured by actigraphy(2) in patients with Irregular Sleep-Wake Rhythm Disorder (ISWRD) and Alzheimer's disease (AD) dementia. This is the first clinical study of lemborexant to assess the circadian rhythm of sleep-wake patterns in this patient population. ISWRD is a type of circadian rhythm sleep disorder where the pattern of sleep and wakefulness that repeats itself over a 24-hour period in healthy individuals is broken down, and sleeping and waking occur instead at various times during the day and night. It is a common comorbid condition in AD, appears early in the course of disease, and is associated with many of the behavioral disturbances in AD patients such as agitation, restlessness and wandering. For elenbecestat, there are two poster presentations scheduled, including a presentation on the use of the International Shopping List Test as the objective assessment of cognitive impairment to identify subjects with early Alzheimer's disease in the phase 3 clinical trials.

Lemborexant, a dual orexin receptor antagonist, is an in-house discovered novel small molecule which inhibits orexin by binding competitively to two subtypes of orexin receptors (orexin receptor 1 and 2). Lemborexant is being jointly developed by Eisai and Purdue Pharma L.P. Elenbecestat, its in-house discovered BACE inhibitor, is being jointly developed by Eisai and Biogen Inc. Two global Phase 3 clinical studies (known as MISSIONAD1 and MISSIONAD2) are ongoing in patients with early AD. In addition, the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of elenbecestat, a process allowing priority reviews by the FDA for drugs deemed as having potential to treat serious conditions and tackle key unmet medical needs.

Furthermore, there will be several oral presentations for anti-A beta antibody aducanumab. Eisai has exercised its option to jointly develop and commercialize aducanumab with Biogen.

Eisai considers dementia a therapeutic area of focus and is committed to new drug development in this field. Eisai strives to bring promising therapies to patients worldwide as early as possible.

(1) The generic name is not yet fixed at this time.
(2) Actigraphy is a non-invasive method for measuring and assessing the circadian rhythm of sleep-wake patterns continuously over several weeks through a device worn on the wrist.

Contact:

Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120

Source: Eisai
Sectors: BioTech

Related Press Release

Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)

April 18 2024 09:53 JST

Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan

April 17 2024 15:17 JST

French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics

April 03 2024 15:24 JST

Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

April 01 2024 08:39 JST

Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical

March 29 2024 14:51 JST

Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture

March 29 2024 14:19 JST

Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024

March 29 2024 13:32 JST

Lifenet and Eisai Co-Develop Dementia Insurance "be"

March 21 2024 16:36 JST

Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace

March 21 2024 15:10 JST

Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients

March 06 2024 16:47 JST

More Press release >>

Latest Press Release

JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan
Apr 26, 2024 10:00 JST

Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024
Apr 25, 2024 18:21 JST

MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park
Apr 25, 2024 17:45 JST

GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series
Apr 25, 2024 16:50 JST

Toyota Exhibiting at Beijing Motor Show 2024
Apr 25, 2024 16:25 JST

Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada
Apr 25, 2024 11:10 JST

UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh
Apr 25, 2024 09:00 JST

Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date
Apr 24, 2024 17:19 JST

MC and Denka Sign J/V Agreement in Fullerene Business
Apr 24, 2024 17:02 JST

Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST

NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST

Fujitsu SX Survey reveals key success factors for sustainability
Apr 23, 2024 10:25 JST

Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions
Apr 22, 2024 16:09 JST

NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II
Apr 22, 2024 15:09 JST

Soft Space Launches the First and Only JCB Payment Gateway in Malaysia
Apr 22, 2024 15:00 JST

TOYOTA GAZOO Racing takes a one-two in Croatian thriller
Apr 22, 2024 10:47 JST

First-ever Mazda CX-80 Crossover SUV Unveiled in Europe
Apr 19, 2024 13:50 JST

Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces
Apr 19, 2024 10:17 JST

Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas
Apr 18, 2024 17:01 JST

Toyota Launches All-New Land Cruiser "250" Series in Japan
Apr 18, 2024 13:39 JST

More Latest Release >>